Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia by Schwarz, Emanuel et al.
Biomarker Insights 2010:5 39–47
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Biomarker Insights 2010:5  39
Biomarker Insights
OrIgInAL reseArch
Validation of a Blood-Based Laboratory Test to Aid  
in the Confirmation of a Diagnosis of Schizophrenia
emanuel schwarz1, rauf Izmailov2, Michael spain2, Anthony Barnes2, James P. Mapes2, Paul c. 
guest1, hassan rahmoune1, sandra Pietsch1, F. Markus Leweke3,4, Matthias rothermundt5, Johann 
steiner6, Dagmar Koethe3, Laura Kranaster3,4, Patricia Ohrmann5, Thomas suslow5, Yishai Levin1, 
Bernhard Bogerts6, nico (JM) van Beveren7, george McAllister8, natalya Weber9, David niebuhr9, 
David cowan9, robert h. Yolken10 and sabine Bahn1
1Institute of Biotechnology, University of cambridge, cambridge, UK (consultants to rules-Based Medicine).  
2rules-Based Medicine, Inc., Austin, Texas, UsA. 3Department of Psychiatry and Psychotherapy, University of cologne, 
germany. 4central Institute of Mental health, University of heidelberg, Mannheim, germany. 5Department of Psychiatry, 
University of Muenster, germany. 6Department of Psychiatry, University of Magdeburg, germany. 7Department of 
Psychiatry, erasmus University, Medical center, rotterdam, netherlands. 8Psynova neurotech Ltd (a subsidiary  
of rules-Based Medicine), cambridge, UK. 9Walter reed Army Institute of research, silver spring, Maryland, UsA.  
10The stanley Medical research Institute, chevy chase, MD, UsA. email: es404@cam.ac.uk
Abstract: We describe the validation of a serum-based test developed by Rules-Based Medicine which can be used to help confirm the 
diagnosis of schizophrenia. In preliminary studies using multiplex immunoassay profiling technology, we identified a disease signature 
comprised of 51 analytes which could distinguish schizophrenia (n = 250) from control (n = 230) subjects. In the next stage, these ana-
lytes were developed as a refined 51-plex immunoassay panel for validation using a large independent cohort of schizophrenia (n = 577) 
and control (n = 229) subjects. The resulting test yielded an overall sensitivity of 83% and specificity of 83% with a receiver operating 
characteristic area under the curve (ROC-AUC) of 89%. These 51 immunoassays and the associated decision rule delivered a sensitive 
and specific prediction for the presence of schizophrenia in patients compared to matched healthy controls.
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Introduction
Current  diagnostic  approaches  for  schizophrenia 
are based on patient interviews, which entail a sub-
jective  assessment  of  clinical  symptoms.1 There  is 
increasing interest in the identification of molecular 
abnormalities that can be used to identify, stratify and 
monitor schizophrenia patients. Since longer periods 
of  untreated  psychosis  are  associated  with  poorer 
prognoses,2 an accurate test would enable early inter-
vention  and  improve  patient  outcomes,  providing 
significant reductions of patient morbidity and health 
care costs. In addition, such a test would open up the 
possibility to stratify more accurately the disease and 
could represent a novel translational medicine tool, 
crucial for the discovery and development of more 
efficacious therapies.
One approach in development of a test for schizo-
phrenia is to find a biomarker signature that is capable 
of distinguishing schizophrenia patients from healthy 
controls.  Many  studies  have  identified  molecules 
related to schizophrenia, but these are not likely to 
be useful as a disease test when used as single mark-
ers due to lack of specificity. Recent studies on other 
medical conditions using gene expression approaches 
have  shown  that  multiplexed  biomarkers  can  give 
reproducible  results,  which  have  proven  useful  in 
clinical applications.3
The recent development and application of multi-
plex immunoassay platforms allows the simultaneous 
measurement of many analytes from individual sam-
ples. The Rules-Based Medicine (Austin, TX, USA) 
DiscoveryMAPTM technology has already been applied 
successfully in numerous clinical studies   targeting dis-
eases such as epithelial ovarian cancer,4 scleroderma,5 
coronary artery disease,6 myocardial infarction,7 auto-
immune disorders8 and sickle cell anemia.9 This plat-
form is also suitable for the development of sensitive 
and specific tests for use in medical practice. With this 
in mind, we have used the DiscoveryMAP platform to 
profile serum samples from schizophrenia and control 
subjects.
The first objective of this multicenter study was 
to  identify  a  set  of  analytes  which  were  altered 
reproducibly in schizophrenia patients compared to 
matched healthy controls. The second objective was 
to use this analyte signature to construct a diagnostic 
decision rule, and then validate the signature for its 
utility as a laboratory developed test using another 
large  cohort  of  schizophrenia  patient  and  control 
samples. Both phases of this study were conducted 
in  the  Clinical  Laboratory  Improvement  Amend-
ments  (CLIA)-certified  laboratory  at  Rules-Based 
Medicine.
Methods
The present study consisted of two phases (Fig. 1). 
The first phase was aimed at selection of accurate 
and reproducible schizophrenia biomarkers from 181 
assays  comprising  the  Rules-Based  Medicine  Dis-
coveryMAP assay collection. Phase I resulted in the 
selection of 51 specific immunoassays to be used in 
assay validation. Phase II featured a refinement of 
the individual components of the multiplexed immu-
noassay, development of a decision rule for separat-
ing schizophrenia patients from normal controls, and 
validation of the decision rule using a cohort of 806 
clinical samples. For biological validation of the deci-
sion rule, 480 of these samples were only analyzed 
Phase I: Marker selection Phase II: 51-plex
validation
(using DiscoveryMAPTM-181 analytes) (schizophrenia multiplex-51 analytes)
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during phase II of this study. The protocols for the 
study participants, clinical samples and test methods 
were carried out in compliance with the Standards 
for  Reporting  of  Diagnostic  Accuracy  (STARD) 
initiative.10
study participants
Subjects  were  recruited  from  the  Departments  of 
Psychiatry at the Universities of Cologne (cohort 1), 
Muenster (cohort 2), Magdeburg (cohorts 3 and 4), 
  Rotterdam (cohort 5) and the US military (n = 110 
Bipolar  Disorder  patients  and  n  =  110  controls). 
Cohorts  used  for  the  marker  selection  phase  were 
comprised of 250 first- and recent-onset schizophre-
nia  patients  and  230  control  subjects  (Table  1A). 
  Schizophrenia patients of cohort 1 (n = 71), 2 (n = 46), 
4 (n = 47) and 5 (n = 40) were antipsychotic-naïve 
and 32 out of 46 subjects from cohort 3 had not been 
treated with antipsychotic medication for more than 6 
weeks prior to sample collection. Drug naïve patients 
are difficult to recruit since even large clinical facili-
ties can only expect to diagnose about 20–30 such 
patients each year. To facilitate the future develop-
ment of a test with differential diagnosis capability, 
we  also  carried  out  DiscoveryMAP  analysis  using 
samples from subjects within 30 days before their 
first contact with US military psychiatric services and 
who later received a confirmed diagnosis of bipolar 
disorder (BD) (n = 110, Table 1B). The cohort used 
to validate and implement the decision rule was com-
prised of samples from a mixture of first onset and 
chronic antipsychotic-treated schizophrenia patients 
along with healthy matched controls. The cohort orig-
inally consisted of a total of 838 subjects, 593 sub-
jects   diagnosed with schizophrenia and 245 matched 
healthy controls. During the laboratory testing of the 
Table 1A. Demographic details of subjects included in phase I (biomarker selection).
class cohort 1 2 3 4 5
control n 
M/F 
Age* 
BMI*
59 
31/28 
30 ± 8 
23 ± 4
46 
35/11 
27 ± 9 
na
45 
27/18 
34 ± 12 
24 ± 4
40 
33/07 
27 ± 4 
na
40 
26/14 
36 ± 11 
24 ± 3
schizophrenia 
first onset
n 
M/F 
Age* 
BMI*
71 
42/29 
31 ± 10 
24 ± 5
46 
35/11 
27 ± 9 
22 ± 2
46 
30/16 
35 ± 12 
26 ± 5
47 
36/11 
26 ± 8 
na
40 
27/13 
35 ± 10 
25 ± 5
*values are shown as mean ± sd.
samples, 32 samples were found to be of insufficient 
serum   quantity, leaving a final   validation population 
of 577 subjects diagnosed with schizophrenia and 229 
healthy, matched subjects recruited at the Universities 
of Cologne, Muenster and Magdeburg (Table 2).
Schizophrenia was diagnosed based on the Struc-
tured Clinical Interview for Diagnostic and Statisti-
cal Manual (DSM)-IV. Patients used for phase I of 
this study fulfilled the criteria of the paranoid subtype 
(DSM-IV  295.30). All  diagnoses  and  clinical  tests 
were performed by psychiatrists following Good Clin-
ical Practice guidelines. Patients whose clinical diag-
nosis required revision at a later stage were excluded 
from the study. Control subjects used in phase I of 
this study were matched to the schizophrenia patients 
for age, gender and social demographics and were 
recruited from the same economic and geographical 
area of the university districts. Controls with a fam-
ily history of mental disease or with other medical 
conditions such as type II diabetes, hypertension, car-
diovascular or autoimmune diseases were excluded 
from  the  study.  Pre-symptomatic  BD  patients  and 
respective controls (n = 110) were selected from a 
US military serum bank comprising approximately 
43 million sera, which facilitated matching for age, 
gender, ethnicity and lifestyle.
serum samples
The  medical  faculty  ethical  committees  of  the 
  respective research facilities approved the protocols 
of the study. Informed consent was given in writing 
by all participants recruited at universities and clini-
cal investigations were conducted according to the 
  principles expressed in the Declaration of   Helsinki. 
Blood  samples  were  collected  from  all  subjects 
between  8:00  and  12:00  hours  into  S-Monovette schwarz et al
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7.5 mL serum tubes (Sarstedt; Numbrecht,   Germany). 
The samples were left at room temperature for 2 hours 
to allow for blood coagulation and then centrifuged at 
4000 × g for 5 minutes. The resulting supernatants 
were stored at -80 °C in Low Binding Eppendorf 
tubes (Hamburg, Germany).
DiscoveryMAP multiplex  
immunoassay profiling
Analytes  were  measured  in  250  µL  serum  sam-
ples  using  the  DiscoveryMAP  multiplexed  antigen 
  immunoassays  in  the  CLIA-certified  laboratory  at 
Rules-Based Medicine. Assays were calibrated using 
duplicate 8-point standard curves and raw intensity 
measurements were converted to absolute protein con-
centrations using proprietary software. Machine per-
formance was verified using quality control samples 
at low, medium and high levels for each analyte. All 
standard and quality control samples were analyzed 
in a complex matrix to match the sample background. 
Serum samples were analyzed at optimized dilutions 
and  analytes  exceeding  the  highest  concentrations 
on calibration curves were assigned the concentra-
tion of the highest standard, and those assayed below 
minimum concentrations were assigned the value 0.0. 
Assay reproducibility was assessed by reanalysis of 
the same samples approximately three months later 
by using Pearson’s correlation coefficients and moni-
toring the shift in average measurement levels.
Biomarker selection—phase I
The biomarker selection phase of the present study 
was  aimed  at  identification  of  analytes  that  were 
altered  reproducibly  in  schizophrenia  compared  to 
control subjects across independent cohorts (Fig. 1). 
Analytes were ranked based on the number of centers 
in which significant differences were observed using 
unpaired, two-tailed t-tests (P , 0.05). Analyte selec-
tion was guided by the following criteria: i) repro-
ducibility (including the same directional change) in 
three or more centers, ii) high correlation (.0.8) and 
low average measurement shifts (,40%) in repeat 
measurement (see above) and iii) mean experimen-
tal values distant from the least detectable dose (.20 
fold; LDD is defined as the average of the signal plus 
3 standard deviations of 20 blank samples analyzed at 
the same time).
51-plex development and clinical 
validation—phase II
Efficient analysis of the 51 analytes required con-
struction  of  new  multiplexes.  This  procedure  was 
guided  by  optimum  dilution  of  serum  and  mixing 
of antibodies to give the most sensitive assays. The 
required dilutions of serum were 1:5, 1:50, 1:200, 
1:10,000, and 1:200,000. The 1:5 dilution group con-
sisted of 31 analytes which were divided into 4 mul-
tiplexes. For each higher dilution, only one multiplex 
was used, yielding a total of 8 new multiplexes for 
Table 2. Demographic details of 707 subjects used   during 
phase II (51-plex validation). 99 patient follow up   samples 
were  available  from  cohort  2,  yielding  a  total  sample 
  number of 806.
class cohort 1 2 3
control n 
M/F 
Age* 
BMI*
72 
31/40* 
31 ± 9 
24 ± 3
84 
41/43 
37 ± 14 
na
73 
51/22 
34 ± 11 
25 ± 4
schizophrenia  
first onset 
  Drug naïve  n 
M/F 
Age* 
BMI*
132 
78/54 
30 ± 9 
23 ± 4
18 
14/4 
28 ± 9 
22 ± 3
56 
36/20 
37 ± 11 
25 ± 5
  Treated  n 
M/F 
Age* 
BMI*
130 
73/56* 
34 ± 12 
25 ± 5
71 
49/22 
26 ± 8 
24 ± 4
schizophrenia  
chronic
  Drug free n 
M/F 
Age* 
BMI*
11 
8/3 
32 ± 9 
26 ± 6
  Treated n 
M/F 
Age* 
BMI*
60 
32/28 
33 ± 9 
26 ± 5
*Demographic information for one patient not available.
Table 1B. Demographic details of pre-symptomatic bipo-
lar disorder and control subjects.
control n 
M/F 
Age*
110 
70/40 
21 ± 4
Pre-symptomatic Bipolar n 
M/F 
Age*
110 
70/40 
21 ± 4
*values are shown as mean ± sd.Blood-based test to aid in diagnosis of schizophrenia
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the 51 analytes. Once the multiplexes were created, 
large batches of reagents were manufactured to allow 
consistent  testing  of  approximately  7000  samples. 
The  reagents  were  validated  using  the  following 
parameters:  sensitivity,  linearity,  spike  recovery, 
common serum matrix interferences, cross-  reactivity, 
precision, correlation, freeze-thaw stability and short-
term room temperature antigen stability.
Classification decision rule—design 
and optimization
To discriminate schizophrenia patients from controls 
using the markers selected in phase I of this study, 
we  implemented  a  linear  support  vector  machine 
(SVM) algorithm. This method minimized errors by 
counting each misclassified observation with a pen-
alty parameter C. Specific penalty parameters were 
chosen for patients (CSZ) and controls (CNC), and the 
ratio F = CSZ/CNC was varied to modify the balance 
between sensitivity and specificity (visualised in a 
receiver operating characteristic (ROC) curve). Given 
a pair of parameters C and F, all elements of the data 
set were used to train the algorithm, and performance 
was measured using 10-fold cross validation (CV). 
The measured sensitivity and specificity calculated in 
each CV round were averaged and designated as the 
sensitivity and the specificity of the decision rule for 
the parameters C and F.
The optimization process was carried out using an in 
house developed code (Matlab 2009a). The search for 
optimal performance was performed among 3,100 pairs 
of  parameters  (C,F)  covering  the  following  ranges: 
log2C = -10.0 to 0.0 with step 0.1 (100 values in total). 
log2F = -1.5 to +1.5 with step 0.1 (31 values in total).
We also computed the conditional probability C 
that a subject with a given score S is a schizophre-
nia patient. The computation of the conditional prob-
ability was based on the methodology developed by 
Vapnik.11 The conditional probabilities were used to 
augment the accuracy estimation of binary classifica-
tion decision rules with various levels of confidence.
Results and Discussion
schizophrenia biomarker  
selection—phase I
The  first  stage  of  the  biomarker  selection  process 
resulted  in  the  identification  of  22  markers  of  the 
  DiscoveryMAP  assay  platform  which  were  altered 
in the schizophrenia population in three or more of 
the  clinical  centers  (Fig.  2A). Technical  reproduc-
ibility was assessed by repeating the measurements 
(n = 63 subjects) approximately 3 months later. This 
showed an average correlation of 0.83, an average 
measurement shift of 29% and an average log dis-
tance to the LDD of 1.29. In contrast, analytes that 
were not selected featured an average correlation of 
0.65, measurement shift of 54% and log distance to 
the LDD of 0.70.
Nine  additional  biomarkers  were  incorporated 
into the 51-plex due to their known association with 
schizophrenia or due to the fact that we identified sig-
nificant changes in these analytes in studies of schizo-
phrenia patients using orthogonal platforms (Fig. 2B). 
In addition, we compared 110 pre-symptomatic bipo-
lar disorder patients with 110 matched controls and 
incorporated significant analytes (n = 20, parametric 
two-tailed t-test, P , 0.05) to facilitate the future 
development  of  a  test  with  differential  diagnosis 
capability (Fig. 2C).
Decision rule development 
and performance
New  multiplexed  immunoassays  were  developed 
which  measured  all  51  analytes.  These  were  used 
to  analyze  a  cohort  of  806  subjects  comprised  of 
577 schizophrenia and 229 control subjects. For tech-
nical  validation,  these  also  contained  227  samples 
which had been used previously during the marker 
selection phase (phase I, Fig. 1) of the study. The aver-
age correlation for markers with high measurement 
quality (indicated by “+” in the correlation column of 
Fig. 2) between phase I and phase II using 84 controls 
out of the 227 samples was 0.86 (range: 0.71–0.99), 
indicating  good  reproducibility.  Two  classification 
decision rules were constructed using SVM. The first 
decision rule (SVM-A) was optimized to discriminate 
schizophrenia patients from controls in the combined 
dataset of 806 subjects. This yielded a cross-valida-
tion classification accuracy of 83% (sensitivity 83%, 
specificity 83%, ROC-AUC 89%). Since the cohort 
contained multiple samples from 99 antipsychotic-
treated patients, a second decision rule (SVM-B) was 
built using only the 707 unique samples. This decision 
rule also yielded a good separation between patients 
and controls with a cross-validation accuracy of 83% schwarz et al
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(sensitivity 83%, specificity 82%, ROC-AUC 88%). 
Fig. 3A displays the classification accuracy and cor-
responding regions of conditional probabilities which 
are  further  detailed  in  Figure  3B.  The  conditional 
probability of correct classification of schizophrenia 
and control subjects increased with higher or lower 
scores relative to the decision boundary (Figure 3D 
lower panel).
To  obtain  an  unbiased  estimate  of  classifica-
tion performance and a biological validation of the 
schizophrenia analyte signature, we determined the 
performance of the decision rules in samples which 
had not been used for marker selection in phase I. 
Application of SVM-B (n = 480 subjects) yielded an 
overall    classification  accuracy  of  84%  (conditional 
  probabilities are shown in Table 3). We also deter-
mined the classification accuracy of the SVM-B deci-
sion rule for four regions of conditional probabilities 
(Table 4). This resulted in an increase in accuracy of 
up to 96% for schizophrenia patients and up to 97% for 
controls in the highest probability regions (Table 4). 
When  Region  III  was  designated  as  indeterminate, 
17% of the total number of subjects were excluded 
(SVM-A, 20% for SVM-B).
Out of the 478 total schizophrenia patients included 
in phase II, 111 were suffering from a non-paranoid 
type of the disease (Table 5). SVM-A identified 95 
(86%) of these patients correctly suggesting that the 
biomarker  signature  was  present  regardless  of  the 
schizophrenia subtype.
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Figure 2. selection of analytes incorporated into the 51-plex. A) selection of 22 analytes was guided by (1) reproducible changes across independent 
cohorts of schizophrenia patients and controls (green plus; P , 0.05 in 3–5 cohorts), (2) consistent directional fold-change (green plus), (3) good cor-
relation (r . 0.8), (4) a low shift (,40%) between the first and second quality control measurements and (5) a high measurement to LDD ratio (.20:1) 
(X = lower, -- = not tested). B) 9 analytes were selected that are known to be involved in schizophrenia from the scientific literature or that we have identi-
fied as being differentially expressed using orthogonal platforms. c) 20 analytes were also selected which showed significant changes in bipolar disorder 
patients compared to controls.Blood-based test to aid in diagnosis of schizophrenia
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Table 3. Classification performance of SVM-B in phase II (51-plex development). Accuracy estimates are shown for the 
entire set of samples from unique patients as well as for the subset of 480 samples which were not used during phase I of 
the study. The conditional probability estimate is the median of all conditional probabilities in the respective group.
Group Subgroup sVM-B SVM-B (480 validation samples)
n  Classification 
accuracy
conditional 
probability
n  Classification 
accuracy
conditional 
probability
controls 229 83% 0.69 116 77% 0.61
schizophrenia Fe drug naive 189 77% 0.86 111 78% 0.85
Fe treated 201 85% 0.91 173 86% 0.91
chronic 71 96% 0.94 71 96% 0.94
Abbreviation: FE, first episode.
We also investigated 80 subjects (baseline Posi-
tive  and  Negative  Syndrome  Scale  [PANSS]  of 
66.0 ± 17.8) before and after 4–6 weeks of antip-
sychotic  treatment  which  resulted  in  an  overall 
reduction in symptoms of 13% (average reduction 
of 10.3 ± 17.3), as measured using the Positive and 
Negative Syndrome Scale (PANSS positive = 18% 
lower  [average  reduction  of  3.7  ±  4.1],  PANSS 
  negative = 8% lower [average reduction of 1.6 ± 4.9], 
PANSS general = 12% lower [average reduction of 
5.0 ± 8.5]).12 Interestingly, SVM-B was capable of 
identifying 85% of these patients at the first time-point 
and after the treatment period. There was an average 
correlation of 0.49 across all 51 analytes,   supporting schwarz et al
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the  stable  identification  capability  of  the  decision 
rule. This  suggested  that  schizophrenia  patients  in 
remission still feature schizophrenia-like serum pro-
files even after 4–6 weeks of treatment.
Conclusions
In this multicenter study, we discovered and validated 
a biomarker panel for schizophrenia based on bio-
logical and technical reproducibility of the molecular 
signature. All stages of the process, including con-
duction of the assays, analyte selection, biomarker 
panel  refinement  and  development  of  the  decision 
rule,  were  carried  out  in  a  CLIA-certified  labora-
tory at Rules-Based Medicine. Biomarker selection 
was based on a large number of samples collected 
from antipsychotic naïve, acutely psychotic patients 
to facilitate relatively uniform conditions. Subjects 
were recruited from four independent clinical centers 
and samples were collected according to strict stan-
dard   operating   procedures to maximize   reliability and 
accuracy of the results. Biological variability arising 
from the collection in different geographical regions 
may contribute to the generality of the present find-
ings. Another factor which should be considered in 
this regard is that the samples were collected at the 
same centers for phases I and II of the study. How-
ever,  as  the  data  were  generated  from  three  inde-
pendent centers and from independent subjects, it is 
likely that the findings will be generalizable to other 
clinical centers. As the assay progresses from beta 
site testing to analysis in different subpopulations, 
the  performance  against  present  clinical  classifica-
tion and observed prevalence and incidence must be 
monitored and differences will need examination.
The implementation of the 51 marker decision rule 
was  based  on  a  cohort  comprised  of  both  untreated 
and  treated  schizophrenia  patients  who  were  either 
  experiencing a first episode of illness or who were chron-
ically ill (54% of patients were on current   antipsychotic 
treatment). This collection is likely to represent more 
closely the patient population encountered in clinical 
practice. High classification performance demonstrated 
that  the  decision  rule  could  identify  schizophrenia 
patients with high accuracy irrespective of the disease 
duration or treatment state. Interestingly, the biomarker 
signal was still apparent in subjects even after 4–6 weeks 
of successful treatment with antipsychotic medication. 
This suggests that the 51-plex is robust for identification 
of subjects with schizophrenia at different stages of the 
schizophrenia disease process. Further work is required 
for the development of a biomarker panel aiding in the 
monitoring of patient responses to treatment.
In summary, the present findings demonstrate the 
applicability of a rapid and non-invasive test to   confirm 
the  presence  of  schizophrenia. This  first  attempt  to 
develop a molecular test with clinical utility for the 
Table 4. Classification performance of SVM-B in phase II (51-plex development). Accuracy estimates are shown for the 
entire set of samples from unique patients as well as for the subset of 480 samples which were not used during phase I of 
the study. Individual estimates are given for four regions of conditional probabilities.
probability 
region
conditional 
probability
sVM-B SVM-B (480 validation samples)
n patients 
(%)
n controls 
(%)
Classification 
accuracy#
n patients 
(%)
n controls 
(%)
Classification 
accuracy#
region I 1.00–0.91 234 (49%) 9 (4%) 96% 186 (51%) 0 (0%) 100%
region II 0.91–0.68 128 (27%) 17 (7%) 88% 119 (32%) 21 (18%) 85%
region IV* 0.60–0.83 31 (6%) 60 (26%) 73% 20 (5%) 39 (34%) 66%
region V* 0.83–0.84 2 (0.4%) 84 (37%) 97% 1 (0.2%) 21 (18%) 95%
*The conditional probabilities in regions marked with an asterisks reflect those determined for controls.
#Classification accuracies reflect the percentage of correct patient identifications in regions I and II and correct control identifications in regions IV and V.
Table  5.  subtypes  of  the  478  schizophrenia  patients 
  investigated in phase II of this study.
DSM-IV  
code
Subtype n
295.1 schizophrenia, disorganized type 18
295.2 schizophrenia, catatonic type 7
295.3 schizophrenia, paranoid type 367
295.4 schizophreniform disorder 26
295.6 schizophrenia, residual type 3
295.7 schizoaffective disorder 27
295.9 schizophrenia, undifferentiated type 15
297.1 Delusional disorder 1
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diagnosis  of  schizophrenia  was  focused  on  the  dis-
tinction of schizophrenia patients against healthy con-
trols. For this application, we have developed a refined 
51-plex assay panel and decision rule with a sensitivity 
and specificity of 83%. We anticipate that the 51-plex 
assay panel will result in the future development of a 
differential diagnostic test that can distinguish among 
various neuropsychiatric disorders such as schizophre-
nia,  bipolar  disorder  and  major  depressive  disorder. 
Therefore, the next stage towards clinical translation is 
to conduct a large scale clinical validation study using 
samples from diverse psychiatric patient populations 
and settings in a series of prospective studies with the 
Rules-Based Medicine assay platform.
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